Antihemostatic and antithrombotic effects of monoclonal antibodies against von Willebrand factor in nonhuman primates.
BACKGROUND
Because the adhesive glycoprotein von Willebrand Factor (vWF) mediates initial platelet attachment at sites of vascular injury and may also contribute to shear-dependent platelet thrombus formation, we have determined in vivo the relative antithrombotic efficacy and hemostatic safety of infusing murine monoclonal antibodies against vWF.


METHODS
In baboons with chronic arteriovenous shunts, thrombus formation was initiated by interposition of thrombogenic Dacron vascular grafts (VG) and endarterectomized baboon aortic segments (EAS). Thrombus formation on VG and EAS was assessed by use of real-time scintillation camera imaging of indium 111-labeled platelet deposition. In control and treated animals (anti-vWF antibody) platelet hemostatic competence was evaluated by means of serial measurements of platelet count, bleeding time, and ex vivo platelet aggregation in response to adenosine diphosphate and ristocetin.


RESULTS
Although bolus antibody infusions did not affect circulating platelet counts, bleeding times were immediately prolonged to 28 +/- 4 minutes (vs 4.7 +/- 0.4 minutes before treatment, p = 0.01). Bleeding times normalized within 24 hours after antibody administration. Platelet aggregation in response to adenosine diphosphate was unchanged by antibody therapy, whereas ristocetin-induced platelet aggregation was abolished acutely and remained impaired for 24 hours. Platelet deposition on VG after 60 minutes of exposure to flowing blood was 2.95 +/- 0.74 x 10(9) platelets/cm in six control animals as compared to 1.86 +/- 0.16 x 10(9) platelets/cm in five treated animals (p = 0.04). Similarly, platelet deposition on EAS averaged 4.40 +/- 0.89 x 10(9) platelets/cm in control studies and was reduced significantly by antibody therapy (1.52 +/- 0.50 x 10(9) platelets/cm, p = 0.02).


CONCLUSIONS
Despite profound interruption of platelet hemostatic functions, therapeutic targeting of vWF modestly inhibits platelet-dependent thrombosis.
Krupski
W C
WC
Department of Medicine, Emory University School of Medicine, Atlanta, Ga.
Bass
A
A
Cadroy
Y
Y
Kelly
A B
AB
Harker
L A
LA
Hanson
S R
SR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D001011:Aorta / Q000502:physiology / Q000601:surgery; D001166:Arteriovenous Shunt, Surgical; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D001807:Blood Vessel Prosthesis; D004691:Endarterectomy; D006487:Hemostasis / Q000187:drug effects*; D008297:Male; D010215:Papio; D012016:Reference Values; D012039:Regional Blood Flow; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D014654:Vascular Patency / Q000187:drug effects; D014841:von Willebrand Factor / Q000276:immunology*
D000911:Antibodies, Monoclonal; D014841:von Willebrand Factor